Melphalan Accord-Uk

Melphalan, the active ingredient in Melphalan Accord-Uk, is an alkylating agent presented as a sterile powder for intravenous use. It is employed in the treatment of multiple myeloma, ovarian cancer, melanoma and neuroblastoma in adult patients.

GNH USA supplies Melphalan Accord-Uk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is an alkylating antineoplastic used in several solid‑tumour and hematologic malignancies.

Multiple myeloma: contributes to disease control and prolongs survival when combined with other chemotherapy agents. Ovarian cancer: used as part of high‑dose regimens to improve response rates. Melanoma: administered in metastatic settings to achieve tumor reduction. Neuroblastoma: incorporated into intensive protocols for high‑risk pediatric patients.

Melphalan may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting: frequent gastrointestinal upset during and after infusion. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Alopecia: temporary hair loss during treatment cycles. - Fatigue: persistent tiredness affecting daily activities.

Serious or Rare Side Effects: - Secondary malignancies: risk of developing new cancers after prolonged exposure. - Pulmonary fibrosis: scarring of lung tissue leading to breathing difficulties. - Severe infection: opportunistic infections due to immune suppression. - Hemorrhagic cystitis: bladder inflammation with bleeding. - Renal toxicity: impaired kidney function in susceptible patients. - Cardiac arrhythmia: irregular heart rhythms in high‑dose settings.

Use of Melphalan requires careful monitoring and specific safety measures.

Monitor blood counts: perform regular CBCs to detect myelosuppression early. Assess renal function: evaluate creatinine clearance before each dose. Avoid in pregnancy: drug is contraindicated due to teratogenic risk (Category D). Use protective handling: wear gloves and avoid aerosol generation during preparation. Adjust for hepatic impairment: consider dose reduction in patients with liver dysfunction. Store at controlled room temperature: keep in original container, protect from light and moisture.

Melphalan can interact with several drug classes, influencing safety and efficacy.

Major Interactions (Avoid): - Live vaccines: contraindicated because of immunosuppression. - Myelotoxic agents: concurrent use heightens bone‑marrow suppression. - Nephrotoxic drugs: combined exposure increases risk of renal injury.

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may alter melphalan clearance. - Anticoagulants (e.g., warfarin): increased bleeding tendency. - Azole antifungals (e.g., fluconazole): potential effect on drug metabolism.